JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
21/12/18 - 11:30
DiaSorin launches 3 new primer pairs for use in molecular testing (438.25 KB)
04/12/18 - 8:00
DiaSorin's stocks listed in the FTSE MIB (464.63 KB)
19/11/18 - 15:00
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the United States (435.43 KB)
07/11/18 - 13:00
DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018 (961.72 KB)
17/10/18 - 11:51
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the european market (147.78 KB)
12/10/18 - 11:47
DiaSorin launches Simplexa VZV Direct molecular assay in the european market (444.81 KB)
09/10/18 - 11:35
DiaSorin and Meridian enter into a strategic collaboration to sell Helicobacter pylori stool antigen test in the United States and in the United Kingdom (471.21 KB)
17/09/18 - 11:28
DiaSorin launches the new LIASON quantiFERON-TB Gold Plus assay as an aid for latent tuberculosis detection in partnership with Qiagen (753.85 KB)
07/08/18 - 8:45
Communication on total amount of voting rights (305.24 KB)
02/08/18 - 12:45
The Board of Directors approves the results for the first half of 2018 (883.1 KB)
27/07/18 - 12:00
DiaSorin launches Hepatitis Delta (HDV) test on LIAISON XL platform (735.03 KB)
03/07/18 - 18:30
Conclusion treasury shares buy-back plan (397.33 KB)
03/07/18 - 18:30
Annex 3F (treasury shares buy back July 2018) (6.59 KB)
03/07/18 - 18:30
Report treasury shares buy-back (287.99 KB)
03/07/18 - 18:30
Annex 3F (treasury shares buy back June 2018) (8.69 KB)
29/06/18 - 18:15
Weekly report treasury shares buy-back (290.62 KB)
22/06/18 - 20:30
Weekly report treasury shares buy-back (290.6 KB)
15/06/18 - 21:00
Weekly report treasury shares buy-back (290.62 KB)
12/06/18 - 14:15
DiaSorin introduces primer pair reagents for use in molecular testing: Anaplasma phagocytophilum, Ehrlichia e Babesia (445.17 KB)
08/06/18 - 23:15
Weekly report treasury shares buy-back (290.24 KB)
04/06/18 - 13:15
Annex 3F (treasury shares buy back May 2018) (8.54 KB)
01/06/18 - 20:15
Weekly report treasury shares buy-back (290.38 KB)
25/05/18 - 22:30
Weekly report treasury shares buy-back (289.97 KB)
19/05/18 - 1:45
Weekly report treasury shares buy-back (289.76 KB)
11/05/18 - 20:15
Weekly report treasury shares buy-back (290.77 KB)
08/05/18 - 14:30
The DiaSorin Group reports growth in revenues and profitability in the first quarter 2018 (832.84 KB)
03/05/18 - 20:15
Start up treasury shares buy-back plan (354.27 KB)
24/04/18 - 14:00
Annex 3F (treasury shares buy back) (7.77 KB)
23/04/18 - 18:30
Annual General Meeting 2018 (589.65 KB)
19/04/18 - 21:15
Conclusion treasury shares buy-back plan (397.59 KB)
19/04/18 - 21:00
Weekly report treasury shares buy-back (289.29 KB)
13/04/18 - 20:30
Weekly report treasury shares buy-back (290.07 KB)
06/04/18 - 19:45
Weekly report treasury shares buy-back (288.33 KB)
05/04/18 - 12:00
DiaSorin receives FDA clearance for the LIAISON BRAHMS PCT II GEN assay to detect severe bacterial infections (e.g. Sepsis) (737.88 KB)
04/04/18 - 20:00
Start up treasury shares buy-back plan (346.04 KB)
28/03/18 - 18:45
DiaSorin earns FDA clearence extending sample claims for Simplexa HSV 1 & 2 direct molecular test (442.69 KB)
07/03/18 - 15:30
DiaSorin: FY 2017 Results (1.14 MB)
30/01/18 - 11:45
DiaSorin signs an agreement with the Italian Tax Authority granting tax relief under the Italian Patent Box regime (574.68 KB)
08/01/18 - 9:00
QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems (483.2 KB)
08/01/18 - 9:00
QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems (483.2 KB)
12/12/17 - 13:15
DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)
29/11/17 - 19:30
Resignation of a Strategic Executive of the Company (233.58 KB)
09/11/17 - 14:15
GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)
29/09/17 - 15:00
DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)
29/09/17 - 14:15
DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)
21/09/17 - 12:45
DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)
03/08/17 - 14:45
DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)
28/07/17 - 14:45
DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)
25/07/17 - 21:00
DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)
10/07/17 - 13:30
DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)
26/06/17 - 9:45
DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)
23/06/17 - 9:30
DiaSorin and TECAN to collaborate in new platform development (755.46 KB)
22/06/17 - 19:45
DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)
23/05/17 - 11:45
DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)
16/05/17 - 13:00
DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)
08/05/17 - 19:30
DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)
27/04/17 - 18:45
DiaSorin - Annual General Meeting 2016 (421.04 KB)
21/04/17 - 18:45
DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)
06/04/17 - 18:00
DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)
08/03/17 - 15:30
The Board of Directors approves the results for FY'16 (1.13 MB)
21/02/17 - 11:30
DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)
26/01/17 - 12:45